Merck KGaA's recently acquired SpringWorks unit has claimed EU approval for Ogsiveo, becoming the first approved therapy for ...

The European Commission (EC) has granted marketing authorisation to SpringWorks Therapeutics, a subsidiary of Merck KGaA, for ...

Skyhawk's RNA tech could be Merck's next blockbuster play as drug setbacks and looming patent cliffs force a reinvention.

The European Commission has granted German pharmaceutical giant Merck approval to use the cancer drug Ogsiveo, the ...

The European Commission (EC) granted marketing authorization for Ogsiveo (nirogacestat), an oral gamma secretase inhibitor, ...

OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid ...

Waltham, Massachusetts–based Skyhawk Therapeutics has been collecting collaborations with larger companies in spades since ...

OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumorsSTAMFORD, Conn., Aug. 18, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc., ...

Another pointed to Merck not disclosing a termination of negotiations, which German law would have allegedly required if talks had ended, and reaffirmed their belief in SpringWorks' leadership.

The Neurofibromatosis Type 1 market is expected to surge due to the disease's increasing prevalence and awareness during the ...

– Purchase price of $47 per share in cash represents an equity value of approximately $3.9 billion, or an enterprise value of $3.4 billion (€3.0 billion) – – Planned acquisition will ...

In 2024, Merck KGaA, Darmstadt, Germany, generated sales of € 21.2 billion in 65 countries. The company holds the global rights to the name and trademark “Merck” internationally.